Halozyme Therapeutics stock
HALONASDAQHalozyme Therapeutics, Inc., HealthcareISIN US40637H1095
80Score 80 out of 100, Strong
Price and trend
59 / 100
Price history
+43% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 18% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 19).
The price is 23% below its 52-week high. Largest decline in 20 years: 74% (May 2007 to December 2008).
Chart figures for advanced users
- SMA 50$114.77
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$85.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)19
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$61.63
- The lowest closing price of the last twelve months.
- Resistance$131.18
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Halozyme Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $11.48B, is number 31 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.4B (up 37.6% year on year) and earnings of $316.89M (down 28.6%).
- For fiscal 2026, analysts expect on average revenue of $1.88B (up 34.7%) and adjusted earnings per share of $8.62 (up 108.7%).
Show more
- MEQIRI Score 80 out of 100 (Strong): rank 20 of 702 in Healthcare, median 53.
- The P/E is 25.4 (Biotechnology median 21.7, own median of recent years 25.5).
- Our model puts fair value at $160.66, with the price 37% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 39.2% a year since 2020, Biotechnology median 19.4%.Growth 100
- High return on capitalReturn on invested capital 32.8% in fiscal 2025, Biotechnology median −24.3%.Profitability 97
- Earnings per share growingUp 22.7% a year since 2020.Growth 100
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are growth and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
- high price swings
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $114.76 and expensive above $267.77 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $235.33 (cash-flow model) and $85.99 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 10.3%. At 11.3% the fair value would be $143.54, at 9.3% it would be $184.14.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 45% on the twelve months before. Revenue has grown strongly since 2006, at around 47% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 84%, operating 57%, net 23%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 5 Nov 2026EPS reported $2.39 (expected $2.30)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $8.62+1.3%
- Revenue
- $1.88B+0.9%
- Earnings per share
- $10.42+0.5%
- Revenue
- $2.1B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +23.4%2026 guidance raised: total revenue of $1.835 billion to $1.91 billion (up 31% to 37%), with the midpoint up $112.5 million.
“We now expect total revenue of $1.835 billion to $1.91 billion, representing year-over-year growth of 31% to 37%, driven by an increase in royalty revenue projections and product sales from API.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $26.41M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Torley HelenSale
8 Oct 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $109.40
- Value
- $2.19M
- Torley HelenSale
7 Oct 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $111.55
- Value
- $2.23M
- Torley HelenSale
6 Oct 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $109.58
- Value
- $2.19M
Show 16 more
- Posard Matthew L.Sale
1 Oct 2026, Board
- Shares
- 5,230
- Price
- $108.54
- Value
- $567,661
- Posard Matthew L.Sale
16 Sept 2026, Board
- Shares
- 18,996
- Price
- $107.74
- Value
- $2.05M
- Torley HelenSale
11 Sept 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $107.24
- Value
- $2.14M
- Torley HelenSale
10 Sept 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $107.17
- Value
- $2.14M
- Torley HelenSale
9 Sept 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $107.43
- Value
- $2.15M
- Torley HelenSale
19 Aug 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $107.00
- Value
- $2.14M
- Torley HelenSale
18 Aug 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $104.18
- Value
- $2.08M
- Torley HelenSale
17 Aug 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $102.60
- Value
- $2.05M
- Connaughton BernadetteSale
10 Aug 2026, Board
- Shares
- 1,626
- Price
- $102.80
- Value
- $167,153
- Torley HelenSale
8 Jul 2026, PRESIDENT AND CEO
- Shares
- 1,923
- Price
- $79.77
- Value
- $153,391
- Connaughton BernadetteSale
1 Jul 2026, Board
- Shares
- 1,625
- Price
- $76.71
- Value
- $124,651
- Krishnan MaheshSale
29 Jun 2026, Board
- Shares
- 7,304
- Price
- $75.00
- Value
- $547,800
- Torley HelenSale
3 Jun 2026, PRESIDENT AND CEO
- Shares
- 10,000
- Price
- $69.07
- Value
- $690,653
- Torley HelenSale
2 Jun 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $66.39
- Value
- $1.33M
- Torley HelenSale
1 Jun 2026, PRESIDENT AND CEO
- Shares
- 20,000
- Price
- $67.58
- Value
- $1.35M
- Connaughton BernadetteSale
1 Jun 2026, Board
- Shares
- 1,625
- Price
- $66.21
- Value
- $107,591
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Halozyme Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 80
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Madrigal PharmaceuticalsMDGL $12.44B33
- Pharmaron Beijing300759.SZ $12.15B58
- Summit TherapeuticsSMMT $12.03B34
- Financière de TubizeTUB.BR $11.94B50
- Bio-TechneTECH $11.44B64
- BioMarin PharmaceuticalBMRN $10.98B48
- Sichuan Kelun Pharmaceutical002422.SZ $10.36B69
- VaxcytePCVX $10.24B44
ETFs that hold Halozyme Therapeutics
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.93% | 0.49% | €26.29M |
| iShares Healthcare Innovation UCITS ETF2B78 | 1.42% | 0.40% | €1.5B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.91% | 0.35% | €1.25B |
Show 5 more
| iShares Ageing Population UCITS ETF2B77 | 0.71% | 0.40% | €813.42M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.42% | 0.30% | €5.36B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.26% | 0.43% | €2.5B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.14% | 0.35% | €8.27B |
| Franklin U.S. Equity UCITS ETFFLXU | 0.13% | 0.20% | €56.76M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.